Intellia sets 2023 milestones: NTLA-2001 IND mid-year, $1.3B cash

Intellia Therapeutics, Inc.

Cash, cash equivalents and marketable securities ~$1.3B as of Dec 31, 2022.
NTLA-2001 IND submission mid-2023 for global pivotal trial in ATTR-CM; study start by year-end.
NTLA-2002 (HAE) Phase 2 study initiation and IND submission in 1H 2023.
NTLA-3001 (gene insertion for AATD) IND or equivalent filing in 2H 2023.
Additional clinical data from NTLA-2001 and NTLA-2002 studies expected in 2023.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Intellia Therapeutics, Inc. reported preliminary financial results for the fourth quarter and fiscal year ended December 31, 2022.

Period: the fourth quarter and fiscal year ended December 31, 2022
Result: preliminary results

Exact text from the filing

Although it has not finalized its full financial results for the fourth quarter and fiscal year ended December 31, 2022, Intellia Therapeutics, Inc. (the “Company”) announced on January 5, 2023, that it expects to report that it had approximately $1.3 billion of cash, cash equivalents and marketable securities as of December 31, 2022.

View on SEC.gov

Browse all earnings releases →

Intellia Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-000179

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.